173 related articles for article (PubMed ID: 32494162)
1. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
Wang Y; Wu N; Zhang J; Wang H; Men X
Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
[TBL] [Abstract][Full Text] [Related]
2. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
[TBL] [Abstract][Full Text] [Related]
4. MiR-26a-5p Heightens Breast Cancer Cell Sensitivity to Paclitaxel via Targeting Flap Endonuclease 1.
Cai Y; Zhang T; Chen G; Liu C
Ann Clin Lab Sci; 2023 Jan; 53(1):116-125. PubMed ID: 36889769
[TBL] [Abstract][Full Text] [Related]
5. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
Rasoolnezhad M; Safaralizadeh R; Hosseinpour Feizi MA; Banan-Khojasteh SM; Roshani Asl E; Lotfinejad P; Baradaran B
Mol Biol Rep; 2023 Oct; 50(10):8407-8420. PubMed ID: 37620737
[TBL] [Abstract][Full Text] [Related]
6. Ursolic Acid Reverses the Chemoresistance of Breast Cancer Cells to Paclitaxel by Targeting MiRNA-149-5p/MyD88.
Xiang F; Fan Y; Ni Z; Liu Q; Zhu Z; Chen Z; Hao W; Yue H; Wu R; Kang X
Front Oncol; 2019; 9():501. PubMed ID: 31259152
[TBL] [Abstract][Full Text] [Related]
7. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
8. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
9. Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway.
Bao C; Liu T; Qian L; Xiao C; Zhou X; Ai H; Wang J; Fan W; Pan J
J Cancer; 2021; 12(1):76-88. PubMed ID: 33391404
[No Abstract] [Full Text] [Related]
10. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
Zheng S; Li M; Miao K; Xu H
J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
12. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
13. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG6/miR-125b-5p/BMPR1B Axis: A New Therapeutic Target for Triple-Negative Breast Cancer.
Lv Y; Lv X; Yang H; Qi X; Wang X; Li C; Shang X; Guo H; Zhang J; Zhang Y
Front Oncol; 2021; 11():678474. PubMed ID: 34026654
[TBL] [Abstract][Full Text] [Related]
16. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Guan X; Guan Y
Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
18. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.
Shen X; Lei J; Du L
Exp Ther Med; 2020 Jan; 19(1):375-383. PubMed ID: 31853314
[TBL] [Abstract][Full Text] [Related]
19. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD.
Wu C; Zhao A; Tan T; Wang Y; Shen Z
Exp Ther Med; 2019 Jul; 18(1):550-558. PubMed ID: 31258693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
